Compare CRL & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRL | ENSG |
|---|---|---|
| Founded | 1947 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.4B |
| IPO Year | 1999 | 2007 |
| Metric | CRL | ENSG |
|---|---|---|
| Price | $297.71 | $180.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | $198.27 | ★ $202.60 |
| AVG Volume (30 Days) | ★ 923.3K | 311.1K |
| Earning Date | 05-07-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.14% |
| EPS Growth | N/A | ★ 14.06 |
| EPS | N/A | ★ 3.35 |
| Revenue | $1,857,601,000.00 | ★ $5,057,841,000.00 |
| Revenue This Year | N/A | $17.07 |
| Revenue Next Year | $3.04 | $9.49 |
| P/E Ratio | ★ N/A | $53.44 |
| Revenue Growth | 10.48 | ★ 18.72 |
| 52 Week Low | $144.26 | $141.58 |
| 52 Week High | $300.59 | $218.00 |
| Indicator | CRL | ENSG |
|---|---|---|
| Relative Strength Index (RSI) | 76.44 | 54.74 |
| Support Level | $149.72 | $171.97 |
| Resistance Level | N/A | $183.50 |
| Average True Range (ATR) | 9.71 | 3.87 |
| MACD | 0.64 | -0.76 |
| Stochastic Oscillator | 93.34 | 46.25 |
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.